Could a drug make stem cell transplants safer for blood cancer patients?
NCT ID NCT02356159
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 31 times
Summary
This study tested whether the drug palifermin could make stem cell transplants from unrelated donors safer and more effective for people with blood cancers like leukemia or lymphoma. 34 adults received palifermin before transplant to see if it would reduce severe graft-versus-host disease (GVHD), a serious complication where donor cells attack the patient's body. The goal was to improve immune recovery and overall outcomes after transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
National Marrow Donor Program
Minneapolis, Minnesota, 55401, United States
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.